Analysis of ADR reports caused by cefotaxime sodium in Shandong province and effects of skin test on serious ADR
- VernacularTitle:山东省头孢噻肟钠致ADR报告分析及其皮试对严重的ADR的影响
- Author:
Meijuan REN
1
;
Hongmei ZHANG
2
;
Chang LIU
3
;
Rui LI
1
;
Meixing YAN
3
Author Information
1. School of Medicine and Pharmacy，Ocean University of China，Shandong Qingdao 266000，China
2. Hospital Office，Qingdao Women and Children’s Hospital，Shandong Qingdao 266000，China
3. Dept. of Pharmacy，Qingdao Women and Children’s Hospital，Shandong Qingdao 266000，China
- Publication Type:Journal Article
- Keywords:
cefotaxime sodium;
adverse drug reactions;
safety of drug use;
Shandong province;
skin test
- From:
China Pharmacy
2023;34(10):1233-1236
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the clinical manifestations and characteristics of adverse drug reactions （ADR） caused by cefotaxime sodium in Shandong province， and to explore the effects of skin test before medication of cefotaxime sodium on serious ADR， so as to provide reference for safe drug use in clinic. METHODS The relevant data of cefotaxime sodium-induced ADR reported by Shandong Province ADR Monitoring Center during December 2019 to December 2021 were collected from National ADR Monitoring System. The ADR classification， age， gender， ADR occurrence time， route of administration， history of allergy， primary diseases， ADR systems/organs involved， clinical manifestations， outcome， skin test or not before medication were statistically analyzed. RESULTS A total of 1 057 ADR reports caused by cefotaxime sodium were included. Among them， there were 867 patients （82.02%） with general ADR and 190 patients （17.98%） with serious ADR. The majority were ＜11 years old （40.30%）. The main route of administration was intravenous drip （96.69%）. A total of 1 033 patients （97.73%） developed ADR 30 min to 24 h after medication. A total of 814 patients （77.01%） had no history of allergy. The primary diseases were respiratory system infection （56.58%）. Main systems/organs involved in ADR were skin and its appendants， digestive system and respiratory system， and its clinical manifestations were rash， pruritus， nausea， vomiting， chest tightness， etc. After withdrawal or symptomatic treatment， 1 050 patients （99.34%） were cured or improved. Before the use of cefotaxime sodium， 850 patients underwent skin test （151 patients occurred serious ADR）； there was no statistical significance in the incidence of serious renzhen202102@163.com ADR， compared with the incidence of serious ADR in 207 patients without skin test （39 patients occurred serious ADR）（P＝0.718）. CONCLUSIONS ADR caused by cefotaxime sodium is mainly seen in patients ＜11 years old， mostly occurring 30 min to 24 h after intravenous drip； skin test before medication of cefotaxime sodium cannot reduce the risk of serious ADR. Before using cefotaxime sodium in clinical practice， patients should be asked about their allergy and medication history in detail. During use， it is important to focus on the patient’s condition within 24 h after medication to prevent serious ADR and ensure the safety of clinical medication.
